Artiva Biotherapeutics, Inc. ARTV EBIT

EBIT at other companies

Bristol-Myers SquibbBMY

$4.09B+130%

Gilead SciencesGILD

-$10.39B-520%

Kyverna Therapeutics, Inc.KYTX

-$41.37M+12.7%

Immix Biopharma, Inc.IMMX

-$10.8M-131%

ImmunityBio, Inc.IBRX

-$69.79M-8.3%

Cullinan Therapeutics, Inc.CGEM

-$57.25M+24.5%

FAQ

What is Artiva Biotherapeutics, Inc.'s EBIT?

Artiva Biotherapeutics, Inc. (ARTV) reported EBIT of -$26.89M in Q2 2026.

How has Artiva Biotherapeutics, Inc.'s EBIT changed year-over-year?

Artiva Biotherapeutics, Inc.'s EBIT decreased by 17.9% year-over-year, from -$22.81M to -$26.89M.

What is the long-term trend for Artiva Biotherapeutics, Inc.'s EBIT?

Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s EBIT has grown at a 71.1% compound annual growth rate (CAGR), from -$30.67M to -$89.81M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.